Viral nucleic acid isolation MACHEREY-NAGEL – 05/2018, Rev. 05 Viral nucleic acid isolation 1 Components 1.1 Kit contents NucleoSpin® Dx Virus REF Symbol 50 preps 740895.50 Lysis

US:Tel.: +1 484 821 0984 Fax: +1 484 821 1272 E-mail: [email protected]

MACHEREY-NAGEL GmbH & Co. KG · Neumann-Neander-Str. 6–8 · 52355 Düren · Germany

www.mn-net.com

www.mn-net.comDE / International:Tel.: +49 24 21 969-0Fax: +49 24 21 969-199 E-mail: [email protected]

CH:Tel.: +41 62 388 55 00 Fax: +41 62 388 55 05 E-mail: [email protected]

FR:Tel.: +33 388 68 22 68 Fax: +33 388 51 76 88 E-mail: [email protected]

MACHEREY-NAGEL GmbH & Co. KG · Neumann-Neander-Str. 6–8 · 52355 Düren · Deutschland

www.mn-net.com

www.mn-net.comDE / International:Tel.: +49 24 21 969-0Fax: +49 24 21 969-199 E-Mail: [email protected]

CH:Tel.: +41 62 388 55 00 Fax: +41 62 388 55 05 E-Mail: [email protected]

FR:Tel.: +33 388 68 22 68 Fax: +33 388 51 76 88 E-Mail: [email protected]

EN ISO 9001ZERTIFIZIERT


www.mn-net.com





Viral nucleic acid isolation

User manualNucleoSpin® Dx Virus

Mai 2018/ Rev. 05

In-Vitro Diagnostic Medical Device

740895.50

MACHEREY-NAGEL GmbH & Co. KG D-52355 Düren, Tel: +49 (0) 2421 969 - 0

3MACHEREY-NAGEL – 05/2018, Rev. 05


Table of contents1 Components 4

1.1 Kit contents 4

1.2 Reagents, consumables, and equipment to be supplied by user 5

1.3 About this user manual 5

2 Product description 6

2.1 Intended use 6

2.2 Product use limitations 6

2.3 Quality control 7

2.4 Introduction and kit specifications 7

2.5 Remarks regarding sample quality and preparation 9

2.6 Remarks regarding elution 9

3 Storage conditions and preparation of working solutions 10

4 Safety instructions 11

5 Viral nucleic acid purification with NucleoSpin® Dx Virus 13

5.1 Protocol at a glance 14

5.2 Viral RNA isolation procedure 16

5.3 Viral DNA isolation procedure 18

5.4 Simultaneous viral RNA and DNA isolation procedure 20

6 Appendix 22

6.1 Troubleshooting 22

6.2 Notification requirement 23

6.3 Literature 23

6.4 Ordering information 24

6.5 Product use restriction / warranty 25

MACHEREY-NAGEL – 05/2018, Rev. 054


1 Components

1.1 Kit contents

NucleoSpin® Dx Virus

REF Symbol50 preps

740895.50

Lysis Buffer RAV1 BUF RAV1 35 mL

Wash Buffer RAW BUF RAW 30 mL

Wash Buffer RAV3 (Concentrate)*

BUF RAV3 Conc. 12 mL

RNase-free H2O H2O 13 mL

Elution Buffer RE** BUF RE 13 mL

Carrier RNA (lyophilized) Carrier RNA 1 mg

Proteinase Buffer PB BUF PB 1.8 mL

Proteinase K (lyophilized)* Proteinase K 30 mg

NucleoSpin® Dx Virus Columns (dark blue rings - plus Collection Tubes)

Dx Virus Columns 50

Collection Tubes (2 mL) Collection Tubes 4 x 50

Lysis Tubes (1.5 mL) Lysis Tubes 50

Elution Tubes (1.5 mL) Elution Tubes 50

User manual 1

* For preparation of working solutions and storage conditions see section 3.

** Composition of Elution Buffer RE: 5 mM Tris/HCl, pH 8.5



1.2 Reagents, consumables, and equipment to be supplied by user

Reagents

• 96–100 % ethanol (to adjust nucleic acid binding conditions and to prepare Wash Buffer RAV3)

Consumables

• Disposable pipet tips (aerosol barrier pipet tips are recommended to avoid cross-contamination)

Equipment

• Manual pipettors

• Centrifuge for microcentrifuge tubes

• Vortex mixer

• Heating block or water bath for 70 °C incubation

• Personal protection equipment (e.g., lab coat, gloves, goggles)

1.3 About this user manualIt is strongly recommended to read the detailed protocol section of this user manual. The Protocol at a glance is designed to be used only as a supplemental tool for quick referencing while performing the purification procedure.

MACHEREY-NAGEL user manuals are available on the internet at www.mn-net.com.



2 Product description

2.1 Intended useThe NucleoSpin® Dx Virus kit is a generic system for the manual isolation and purification of viral nucleic acids from human serum or plasma samples for subsequent in-vitro diagnostic purposes. The kit can be used with fresh and frozen human serum and plasma, stabilized with either EDTA or citrate from common blood collection systems. The kit is designed to be used with any downstream application employing enzymatic amplification and detection of RNA and DNA (e.g., RT-PCR, PCR).

The viral nucleic acids isolated and purified with NucleoSpin® Dx Virus can be used in qualitative applications (e.g., RT-PCR or PCR for blood screening) as well as in quantitative applications (e.g., detection of viral load by qPCR) employing diagnostic nucleic acid amplification techniques.

Any diagnostic results generated using nucleic acids isolated with the NucleoSpin® Dx Virus kit in conjunction with an in-vitro diagnostic assay should be interpreted with regard to additional clinical or laboratory findings. To minimize irregularities in diagnostic results, suitable controls for downstream applications (e.g., extraction controls, positive / negative controls) should be used.

The NucleoSpin® Dx Virus kit is intended for use by professional users such as technicians and physicians experienced and trained in molecular biological techniques including experience with serum and plasma samples and viral nucleic acid isolation.

The NucleoSpin® Dx Virus kit does not provide a diagnostic result. It is the sole responsibility of the user to use and validate the kit in conjunction with a downstream in-vitro diagnostic assay.

Besides human samples also fresh and frozen animal samples can readily be used together with the NucleoSpin® Dx Virus kit. Samples include, but are not limited to, serum, plasma, or swabs. It has to be noted that CE IVD labeling of the kit does not apply for animal samples but is limited to human diagnostic use only.

2.2 Product use limitationsThe NucleoSpin® Dx Virus kit is not for use with human whole blood, tissue, stool samples, or cultured cells.

The kit performance has not been evaluated with other cell-free fluid samples like urine or cerebrospinal fluid.

The kit is also neither specified for the isolation and purification of bacterial, fungal, or parasite nucleic acids from human samples nor for the isolation of viral nucleic acids from human swab samples or other sample collections systems.



2.3 Quality controlIn accordance with MACHEREY-NAGEL´s Quality Management System, each lot of NucleoSpin® Dx Virus kit is tested against predetermined specifications to ensure consistent product quality.

2.4 Introduction and kit specificationsNucleoSpin® Dx Virus is based on well-established NucleoSpin® silica membrane technology and provides an easy way to isolate viral RNA and viral DNA simultaneously from 150 µL of serum or plasma samples. Purified RNA and DNA are ready to use for downstream amplifications like RT-PCR or PCR.

The NucleoSpin® Dx Virus procedure is based on a series of simple steps:

First, the serum or plasma samples are lysed in the presence of chaotropic salts. For the purification of viral DNA, Proteinase K is added to the lysis reaction. Lysis buffer and ethanol create appropriate conditions for binding of nucleic acids to the silica membrane of the NucleoSpin® Dx Virus Columns. Carrier RNA improves binding and recovery of low-concentrated viral RNA and DNA. Contaminations (potential PCR inhibitors) like salts, metabolites, and soluble macromolecular cellular components are removed in washing steps with ethanolic buffers RAW and RAV3. The nucleic acids are finally eluted in 50 µL low salt buffer or water.

The linear range of the NucleoSpin® Dx Virus procedure has been determined for HCV RNA and HBV DNA in downstream diagnostic assays (Figures 1 and 2). The kit shows linearity over several orders of magnitude, comprising relevant viral titer for diagnostic purposes.

R2 = 0.996

1

10

100

1000

10000

100000

1000000

0.0001 0.001 0.01 0. 1 1

Sample (10fold dilution)

HB

V IU

/mL

Figure 1 Serial dilution of a plasma sample with high HBV viral load. Real-time PCR of HBV DNA: Artus RealArt HBV DNA, quantification in Roche LightCycler® 480.



R2 = 0.9917

1

10

100

1000

10000

100000

0.001 0.01 0.1 1

Sample (10fold dilution)

HC

V IU

/mL

Figure 2 Serial dilution of a plasma sample with high HCV viral load. Real-time RT-PCR of HCV RNA: Artus RealArt HCV RNA, quantification in Roche LightCycler® 480.

Kit specifications

• NucleoSpin® Dx Virus is designed for the rapid preparation of highly pure viral RNA and DNA (e.g., HCV, HIV, HBV, CMV, H1N1) from plasma and serum.

• NucleoSpin® Dx Virus is suitable for 150 µL serum or plasma samples.

• The viral nucleic acids isolated and purified with NucleoSpin® Dx Virus can be used in qualitative applications (e.g., RT-PCR or PCR for blood screening) as well as in quantitative applications (e.g., detection of viral load by qPCR) employing diagnostic nucleic acid amplification techniques.

• Protocols for isolation of viral RNA, viral DNA, and simultaneous isolation of viral RNA and DNA are included in the user manual.

• The prepared nucleic acids are suitable for applications like automated fluorescent DNA sequencing, RT-PCR, or any kind of enzymatic reaction. The detection limit for certain viruses depends on the individual procedures (e.g., in-house nested (RT-) PCR). To minimize irregularities in diagnostic results, suitable controls for downstream applications (e.g., extraction controls, positive / negative controls) should be used to monitor the purification, amplification, and detection process.

• Besides human samples also fresh and frozen animal samples can readily be used together with the NucleoSpin® Dx Virus kit. Samples include, but are not limited to, serum, plasma, or swabs. It has to be noted that CE IVD labeling of the kit does not apply for animal samples but is limited to human diagnostic use only.



Table 1: Kit specifications at a glance

Parameter NucleoSpin® Dx Virus

Technology Silica membrane technology

Sample material Serum or plasma

Sample volume 150 µL

Elution volume 50 µL

Preparation time 30 min / 4–6 preps

Processing Centrifugation

2.5 Remarks regarding sample quality and preparation • NucleoSpin® Dx Virus is suitable for human serum or plasma samples. For successful

nucleic acid purification, it is important to obtain a homogeneous, clear, and non-viscous sample lysate before adjusting binding conditions and loading the sample onto the NucleoSpin® Dx Virus Column. Check all samples (especially old or frozen samples) for precipitates.

• It is very important to avoid clearing samples by centrifugation / filtration before the RAV1-lysis step, because viruses may be associated with particles or aggregates. Incubation with Buffer RAV1 can be prolonged to dissolve and digest residual cell structures, precipitates and virus particles. However, RNA is sensitive and prolonged incubation may cause decreased yields.

2.6 Remarks regarding elution• Pure nucleic acids are finally eluted under low ionic strength conditions with RNase-

free H2O (pH about 7–8) or slightly alkaline Buffer RE (5 mM Tris-HCl, pH 8.5), both are supplied with NucleoSpin® Dx Virus.

• RNA should be eluted with the RNase-free H2O and DNA with Elution Buffer RE.

• To elute both types of nucleic acids together, use RNase-free H2O provided with the kit, preheated to 70 °C.



3 Storage conditions and preparation of working solutions

Attention: Buffer RAV1 contains guanidinium thiocyanate and Buffer RAW contains guanidine hydrochloride which can form highly reactive compounds when combined with bleach (sodium hypochlorite). DO NOT add bleach or acidic solutions directly to the sample-preparation waste.

• Check all components for damages after receiving the kit. If kit contents like buffer bottles or blister packages are damaged, contact MACHEREY-NAGEL technical support and customer service, or your local distributor.

• Do not use damaged kit components.

• Upon arrival the NucleoSpin® Dx Virus kit should be stored at room temperature (18–25 °C). It is NOT required to open the kit on delivery and remove individual components for separate storage.

• NucleoSpin® Dx Virus Columns can be used until the expiration date on the kit box.

• Use RNase-free equipment.

Before starting the NucleoSpin® Dx Virus protocol prepare the following:

• Lyophilized Proteinase K can be stored at room temperature (18–25 °C) until the expiration date without decrease in performance. Before first use of the kit, add the indicated volume of Proteinase Buffer PB to dissolve lyophilized Proteinase K. Reconstituted Proteinase K should be stored at -20 °C for up to 6 months, but only until the expiration date.

• Carrier RNA: Before first use, add 1 mL Lysis Buffer RAV1 to the Carrier RNA vial. Dissolve the Carrier RNA and pipette the solution back to the RAV1 bottle. Note: Due to the production procedure and the small amount of Carrier RNA contained in the vial, the Carrier RNA may hardly be visible. Lysis Buffer RAV1 including Carrier RNA can be stored at 4 °C for up to 4 weeks. Storage at 4 °C or below may cause salt precipitation. If precipitates are visible, make sure to dissolve all precipitates before use by heating at 40–60 °C for a maximum of 5 min. Carrier RNA dissolved in Buffer RAV1 and stored at -20 °C is stable for at least one year. Do not warm up Buffer RAV1 containing Carrier RNA more than 4 times! Frequent warming, temperatures > 80 °C, and extended heat incubation will accelerate the degradation of Carrier RNA.

• Wash Buffer RAV3: Add the indicated volume (see table below or on the bottle) of ethanol (96–100 %) to Wash Buffer RAV3 Concentrate. Mark the label of the bottle to indicate that the ethanol is added. Store Wash Buffer RAV3 at room temperature. Wash Buffer RAV3 can be stored at room temperature (18–25 °C) for up to one year but only until the expiration date.




REF50 preps

740895.50

Wash Buffer RAV3 (Concentrate) 12 mL Add 48 mL ethanol

Proteinase K 30 mg Add 1.35 mL Proteinase Buffer PB

4 Safety instructionsThe following components of the NucleoSpin® Dx Virus kits contain hazardous contents.

Wear gloves and goggles and follow the safety instructions given in this section.

Only harmful features do not need to be labeled with H and P phrases up to 125 mL or 125 g. Mindergefährliche Eigenschaften müssen bis 125 mL oder 125 g nicht mit H- und P-Sätzen gekennzeichnet werden.

Component Hazard contents GHS symbol

Hazard phrases

Precaution phrases

Inhalt Gefahrstoff GHS-Symbol H-Sätze P-Sätze

RAV1 Guanidine hydrochloride 45–60 %Guanidinhydrochlorid 45–60 %

CAS 593-84-0

WARNINGACHTUNG

302, 412 264W, 273, 301+312, 330

RAW Guanidine hydrochloride 24–36 % + ethanol 35–55 %Guanidinhydrochlorid 24–36 % + Ethanol 35–55 %

CAS 50-01-1, 64-17-5

WARNINGACHTUNG

226, 302 210, 264W, 301+312, 330

Proteinase K Proteinase K, 90–100 %Proteinase K, 90–100 %

CAS 39450-01-6

DANGERGEFAHR

315, 319, 334

261sh, 280sh, 342+311

Hazard phrases

H 226 Flammable liquid and vapour. Flüssigkeit und Dampf entzündbar.



H 302 Harmful if swallowed. Gesundheitsschädlich bei Verschlucken.

H 315 Causes skin irritation. Verursacht Hautreizungen.

H 319 Causes serious eye irritation. Verursacht schwere Augenreizung.

H 334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. Kann bei Einatmen Allergie, asthmaartige Symptome oder Atembeschwerden verursachen.

H 412 Harmful to aquatic life with long lasting effects. Schädlich für Wasserorganismen, mit langfristiger Wirkung.

Precaution phrases

P 210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.

Von Hitze, heissen Oberflächen, Funken, offenen Flammen sowie anderen Zündquellenarten fernhalten. Nicht rauchen.

P 261 Avoid breathing dust / fume / gas / mist / vapours / spray. Einatmen von Staub / Rauch / Gas / Nebel / Dampf / Aerosol vermeiden.

P 264W Wash with water thoroughly after handling. Nach Gebrauch mit Wasser gründlich waschen.

P 273 Avoid release to the environment. Freisetzung in die Umwelt vermeiden.

P 280 Wear protective gloves / protective clothing / eye protection / face protection. Schutzhandschuhe / Schutzkleidung / Augenschutz / Gesichtsschutz tragen.

P 301+312 IF SWALLOWED: Call a POISON CENTER / doctor / … / if you feel unwell. BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt / … anrufen.

P 330 Rinse mouth. Mund ausspülen.

P 342+311 If experiencing respiratory symptoms: Call a POISON CENTER / doctor / … Bei Symptomen der Atemwege: GIFTINFORMATIONSZENTRUM/Arzt / … anrufen.

For further information please see Material Safety Data Sheets (www.mn-net.com). Weiterführende Informationen finden Sie in den Sicherheitsdatenblättern (www.mn-net.com).

When working with the NucleoSpin® Dx Virus kit wear suitable protective clothing (e.g., lab coat, disposable gloves, and protective goggles). For more information consult the appropriate Material Safety Data Sheets (MSDS available online at http://www.mn-net.com/msds).

Caution: Guanidinium thiocyanate in Lysis Buffer RAV1 and guanidine hydrochloride in Wash Buffer RAW can form highly reactive compounds when combined with bleach! Thus, do not add bleach or acidic solutions directly to the sample preparation waste.

The waste generated with the NucleoSpin® Dx Virus kit has not been tested for residual infectious material. A contamination of the liquid waste with residual infectious material is highly unlikely due to strong denaturing lysis buffer and Proteinase K treatment but it cannot be excluded completely. Therefore, liquid waste must be considered infectious and should be handled and discarded according local safety regulations.



5 Viral nucleic acid purification with NucleoSpin® Dx Virus

The procedures below provide instructions for processing a single plasma or serum sample. However, several samples can be processed at the same time; the number depends on the capacity of the microcentrifuge used.

Before starting the preparation:

• Check that Wash Buffer RAV3 and Proteinase K were prepared according to section 3.

• Check that Carrier RNA has been dissolved in Lysis Buffer RAV1 according to section 3.

• Check that 96–100 % ethanol (denatured or non-denatured) is available to adjust nucleic acid binding conditions.

• Set an incubator (e.g., heating block) or water bath to 70 °C.

• Equilibrate the plasma/serum samples to room temperature (18–25 °C). Make sure that the samples are mixed well.

• If a precipitate has formed in Lysis Buffer RAV1 or Buffer RAW, incubate the buffer at 40–60 °C until the precipitate is dissolved.

• Generally, do not mix reagents and columns from different kits and lots.

• Heat RNase-free H2O / Elution Buffer RE to 70 °C for final elution of nucleic acids.

• Do not add Proteinase K solution directly to Lysis Buffer RAV1. The sample has to be combined with the Lysis Buffer RAV1 before addition of Proteinase K.

• All centrifugation steps should be carried out at room temperature (18–25 °C).



5.1 Protocol at a glanceSupplemental protocol-overview:

Carefully read the detailed protocol (section 5.2–5.4) before starting the procedure.

Note: The protocols differ in Proteinase K lysis step (step 3) and elution step (step 24) only.

Viral RNA isolation procedure (section 5.2)

Viral DNA isolation procedure (section 5.3)

Viral RNA + DNA isolation procedure (section 5.4)

Provide sample, lyse viruses, clear lysate

1 150 µL sample in Lysis Tubes

150 µL sample in Lysis Tubes

150 µL sample in Lysis Tubes

2 600 µL Buffer RAV1 containing Carrier RNA

600 µL Buffer RAV1 containing Carrier RNA

600 µL Buffer RAV1 containing Carrier RNA

3 Note: No Proteinase K is used for the isolation of viral RNA only

20 µL Proteinase K (Incubate at least 1 min at room temperature)

20 µL Proteinase K (Incubate at least 1 min at room temperature)

4 Pipette mixture up and down and vortex well

Pipette mixture up and down and vortex well

Pipette mixture up and down and vortex well

5 Incubate at 70 °C for 5 min

Incubate at 70 °C for 5 min

Incubate at 70 °C for 5 min

6 Short spin to clean the lid

Short spin to clean the lid

Short spin to clean the lid

Adjust binding conditions

7 600 µL ethanol 600 µL ethanol 600 µL ethanol

8 Mix by vortexing (10–15 s)

Mix by vortexing (10–15 s)

Mix by vortexing (10–15 s)

Bind RNA/DNA

9 Load 700 µL lysate onto the NucleoSpin® Dx Virus Column

Load 700 µL lysate onto the NucleoSpin® Dx Virus Column

Load 700 µL lysate onto the NucleoSpin® Dx Virus Column

10 8,000 x g, 1 min 8,000 x g, 1 min 8,000 x g, 1 min

11 Transfer the NucleoSpin® Dx Virus Column to a new Collection Tube

Transfer the NucleoSpin® Dx Virus Column to a new Collection Tube




12 Load the residual lysate (ca. 650 µL) onto the column

Load the residual lysate (ca. 650 µL) onto the column

Load the residual lysate (ca. 650 µL) onto the column





Wash silica membrane

15 500 µL RAW 500 µL RAW 500 µL RAW





18 600 µL RAV3 600 µL RAV3 600 µL RAV3





21 200 µL RAV3 200 µL RAV3 200 µL RAV3


Elute RNA/DNA

23 Transfer the NucleoSpin® Dx Virus Column to an Elution Tube

Transfer the NucleoSpin® Dx Virus Column to an Elution Tube

Transfer the NucleoSpin® Dx Virus Column to an Elution Tube

24 50 µL RNase-free H2O (70 °C); Incubate 1–2 min

50 µL Buffer RE (70 °C); Incubate 1–2 min

50 µL RNase-free H2O (70 °C); Incubate 1–2 min




5.2 Viral RNA isolation procedure

1 Provide 150 µL sample in a Lysis Tube (1.5 mL, provided).

2 Add 600 µL Buffer RAV1 containing Carrier RNA to the Lysis Tube.

3 Note: No Proteinase K is used for the isolation of viral RNA only.

4 Pipette mixture up and down and vortex well.

5 Incubate for 5 min at 70 °C.

6 Briefly centrifuge Lysis Tube (approx. 1 s at 2,000 x g) to remove drops from the lid (short spin only).

7 Add 600 µL ethanol (96–100 %) to the clear lysate.

8 Mix by vortexing (10–15 s).

9 Carefully load 700 µL of the lysate onto the NucleoSpin® Dx Virus Column placed in a Collection Tube and close the lid.

10 Centrifuge 1 min at 8,000 x g.

11 Place the NucleoSpin® Dx Virus Column into a new Collection Tube (2 mL, provided) and discard the Collection Tube with flowthrough from the previous step.

12 Load the residual lysate (approx. 650 µL) onto the NucleoSpin® Dx Virus Column and close the lid.



15 Add 500 µL Buffer RAW to the NucleoSpin® Dx Virus Column.



18 Add 600 µL Buffer RAV3 to the NucleoSpin® Dx Virus Column.





23 Place the NucleoSpin® Dx Virus Column into an Elution Tube (1.5 mL, provided) and discard the Collection Tube with flowthrough from the previous step.


NucleoSpin® Dx Virus – viral RNA isolation procedure

24 Add 50 µL RNase-free H2O (preheated to 70 °C) and incubate for 1–2 min.

25 Centrifuge 1 min at 11,000 x g to elute nucleic acid from the column.



5.3 Viral DNA isolation procedure



3 Add 20 µL Proteinase K solution to the Lysis Tube.

Note: Proteinase K is necessary for lysis of DNA viruses.


Note: Make sure that the mixture incubates at least 1 min at room temperature before starting the heat incubation.






















24 Add 50 µL Buffer RE (preheated to 70 °C) and incubate for 1–2 min.




5.4 Simultaneous viral RNA and DNA isolation procedure



3 Add 20 µL Proteinase K solution to the Lysis Tube.

Note: Proteinase K is necessary for lysis of DNA viruses.


Note: Make sure that the mixture incubates at least 1 min at room temperature before starting the heat incubation.



















NucleoSpin® Dx Virus – simultaneuos viral RNA and DNA isolation procedure



24 Add 50 µL RNase-free H2O (preheated to 70 °C) and incubate for 1–2 min.



NucleoSpin® Dx Virus – simultaneuos viral RNA and DNA isolation procedure

6 Appendix

6.1 Troubleshooting

Problem Possible cause and suggestions

Small amounts or no viral nucleic acids in the eluate

Low viral load in the sample

• The nucleic acid yield depends on the viral load in the sample.

Problems with Carrier RNA

• Carrier RNA not added.

• See remarks concerning storage of Buffer RAV1 with Carrier RNA (section 3).

Proteinase K digestion may be necessary

• Choose the appropriate protocol for viral RNA or viral DNA isolation, see section 5.1.

Viral nucleic acids degraded

• Samples should be processed immediately. Ensure appropriate storage conditions up to the processing.

• Check that all buffers have been prepared and stored correctly. If in doubt, use new aliquots of Buffer RAV1, Carrier RNA and Elution Buffer RE.

Problems with subsequent detection

Reduced sensitivity

• Change the volume of eluate added to the PCR / RT-PCR.

Ethanol carry-over

• Prolong centrifugation step (step 22) in order to remove Buffer RAV3 completely.

Please contact: MACHEREY-NAGEL Germany Tel.: +49 (0) 24 21 969 270 e-mail: [email protected]



6.2 Notification requirement “Please note that any serious incident that has occurred in relation to the product shall be reported immediately to the manufacturer and the competent authority of the European member state in which the incident occurred. European vigilance contact points: http://ec.europa.eu/growth/sectors/medical-devices/contacts_de”

6.3 Literature1. Leitfaden Molekulare Diagnostik - Grundlagen, Gesetze, Tipps und Tricks F. Thiemann,

P.M. Cullen, H.-G. Klein, WILEY-VCH 2006, ISBN 3-527-31471-7.

2. Cleavage of Hemagglutinin-Bearing Lentiviral Pseudotypes and Their Use in the Study of Influenza Virus Persistence. Olivier Sawoo, Amélie Dublineau, Christophe Batéjat, Paul Zhou, Jean-Claude Manuguerra, and India Leclercq PLoS One. 2014; 9(8): e106192. Published online 2014 Aug 28. doi: 10.1371/journal.pone.0106192.

3. Addressing false negatives in viral diagnostic polymerase chain reactions: A new approach. Sudarson Sundarrajan, Sneha Rao, Sreesada Parambath, Chandrasekhar Nagaraj, Sriram Padmanabhan and Koteshwara Narasimha Sridhar International Journal of Applied Microbiology and Biotechnology Research, IJAMBR 6 (2018) 32-49.



6.4 Ordering information

Product REF Pack of

CE-IVD marked kits

NucleoSpin® Dx Virus 740895.50 50

NucleoSpin® Dx Blood 740899.50 / .250 50 / 250

Kits for research purposes

NucleoSpin® Virus 740983.10 / .50 / .250 10 / 50 / 250

NucleoSpin® RNA Virus F 740958 25

NucleoSpin® totalRNA FFPE XS 740969.10 / .50 / .250 10 / 50 / 250

NucleoSpin® totalRNA FFPE 740982.10 / .50 / .250 10 / 50 / 250

NucleoSpin® DNA FFPE XS 740980.10 / .50 / .250 10 / 50 / 250

NucleoSpin® Blood 740951.10 / .50 / .250 10 / 50 / 250

NucleoSpin® Tissue 740952.10 / .50 / .250 10 / 50 / 250

NucleoSpin® Tissue XS 740901.10 / .50 / .250 10 / 50 / 250

NucleoSpin® miRNA 740971.10 / .50 / .250 10 / 50 / 250

Proteinase K 740506 100 mg

Collection Tubes (2 mL) 740600 1000

Visit www.mn-net.com for more detailed product information.



6.5 Product use restriction / warrantyThe NucleoSpin® Dx Virus kit is a generic system for the isolation and purification of viral nucleic acids from human plasma or serum samples for subsequent in-vitro diagnostic purposes.

The kit is designed to be used with any downstream application employing enzymatic amplification and detection of RNA and DNA (e.g., RT-PCR, PCR).

Any and all diagnostic results generated using nucleic acids isolated with the NucleoSpin® Dx Virus kit in conjunction with a diagnostic assay should be interpreted with regard to additional clinical or laboratory findings.

The NucleoSpin® Dx Virus kit does not provide a diagnostic result. It is the sole responsibility of the user to use and validate the kit in conjunction with a downstream in-vitro diagnostic assay. ONLY MACHEREY-NAGEL products specially labeled as IVD are suitable for IN-VITRO-diagnostic use.

The NucleoSpin® Dx Virus kit is intended for use by professional users such as technicians and physicians experienced and trained in molecular biological techniques including experience with serum and plasma samples and viral nucleic acid isolation.

For safety instructions please refer to the respective chapter in the user manual. NucleoSpin® Dx Virus kit shall exclusively be used in an adequate test environment, i.e. a suitable laboratory setting. The respective user is liable for any and all damages resulting from application of the NucleoSpin® Dx Virus kit for use deviating from the intended use as specified in the user manual.

This MACHEREY-NAGEL product is shipped with documentation stating specifications and other technical information. MACHEREY-NAGEL warrants to meet the stated specifications. MACHEREY-NAGEL´s sole obligation and the customer´s sole remedy is limited to replacement of products free of charge in the event products fail to perform as warranted. Supplementary reference is made to the general business terms and conditions of MACHEREY-NAGEL, which are printed on the price list. Please contact us if you wish to get an extra copy.

There is no warranty for and MACHEREY-NAGEL is not liable for damages or defects arising in shipping and handling (transport insurance for customers excluded), or out of accident or improper or abnormal use of this product; defects in products or components not manufactured by MACHEREY-NAGEL, or damages resulting from such non-MACHEREY-NAGEL components or products. MACHEREY-NAGEL makes no other warranty of any kind whatsoever, and SPECIFICALLY DISCLAIMS AND EXCLUDES ALL OTHER WARRANTIES OF ANY KIND OR NATURE WHATSOEVER, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE SUITABILITY, REPRODUCTIVITY, DURABILITY, FITNESS FOR A PARTICULAR PURPOSE OR USE, MERCHANTABILITY, CONDITION, OR ANY OTHER MATTER WITH RESPECT TO MACHEREY-NAGEL PRODUCTS. In no event shall MACHEREY-NAGEL be liable for claims for any other damages, whether direct, indirect, incidental, compensatory, foreseeable, consequential, or special (including but not limited to loss of use, revenue or profit), whether based upon warranty, contract, tort (including negligence) or strict liability arising in connection with the sale or the failure of MACHEREY-NAGEL products to perform in accordance with the stated specifications. This warranty is exclusive and MACHEREY-NAGEL makes no other warranty expressed or implied. The warranty provided herein and the data, specifications and descriptions of this MACHEREY-NAGEL product appearing in MACHEREY-NAGEL published catalogues and product literature are MACHEREY-NAGEL´s sole representations



concerning the product and warranty. No other statements or representations, written or oral, by MACHEREY-NAGEL´s employees, agent or representatives, except written statements signed by a duly authorized officer of MACHEREY-NAGEL are authorized; they should not be relied upon by the customer and are not a part of the contract of sale or of this warranty.

Product claims are subject to change. Therefore please contact our Technical Service Team for the most up-to-date information on MACHEREY-NAGEL products. You may also contact your local distributor for general scientific information. Applications mentioned in MACHEREY-NAGEL literature are provided for informational purposes only. MACHEREY-NAGEL does not warrant that all applications have been tested in MACHEREY-NAGEL laboratories using MACHEREY-NAGEL products. MACHEREYNAGEL does not warrant the correctness of any of those applications.

Trademarks:

LightCycler is a registres trademark of the Roche Group NucleoSpin is a trademark of MACHEREY-NAGEL GmbH & Co KG

All used names and denotations can be brands, trademarks, or registered labels of their respective owner – also if they are not special denotation. To mention products and brands is only a kind of information (i.e., it does not offend against trademarks and brands and can not be seen as a kind of recommendation or assessment). Re-garding these products or services we can not grant any guarantees regarding selection, efficiency, or operation.

US:Tel.: +1 484 821 0984 Fax: +1 484 821 1272 E-mail: [email protected]

MACHEREY-NAGEL GmbH & Co. KG · Neumann-Neander-Str. 6–8 · 52355 Düren · Germany

www.mn-net.com

www.mn-net.comDE / International:Tel.: +49 24 21 969-0Fax: +49 24 21 969-199 E-mail: [email protected]

CH:Tel.: +41 62 388 55 00 Fax: +41 62 388 55 05 E-mail: [email protected]

FR:Tel.: +33 388 68 22 68 Fax: +33 388 51 76 88 E-mail: [email protected]


www.mn-net.com





A039590/0780.4

Documents

Viral nucleic acid isolation MACHEREY-NAGEL – 05/2018, Rev. 05 Viral nucleic acid isolation 1 Components 1.1 Kit contents NucleoSpin® Dx Virus REF Symbol 50 preps 740895.50 Lysis